We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics

By LabMedica International staff writers
Posted on 27 Dec 2023
Print article
Image: Slice testing is a relatively new practice that enhances flexibility in germline genetic testing for clinical laboratories (Photo courtesy of 123RF)
Image: Slice testing is a relatively new practice that enhances flexibility in germline genetic testing for clinical laboratories (Photo courtesy of 123RF)

As the discovery of genes linked to a variety of inherited conditions accelerates, clinical labs are finding it increasingly challenging to keep up with multiple assays dedicated to specific disease-related gene panels. To streamline this process, labs are adopting a 'slice testing' approach that employs a comprehensive capture backbone to analyze data pertinent to a specific gene set. Like conventional disease-focused panels, slice testing sequences a wide array of genes but narrows down the analysis to a pre-selected group of pertinent genes. This method combines the benefits of high-quality gene panels with the wider scope and adaptability of exome sequencing.

The Association for Molecular Pathology (AMP, Rockville, MD, USA) has released a detailed report that explores the unique aspects of employing a slice testing strategy for diagnostic purposes. This includes the intricacies of gene selection, analytical performance, coverage, quality, and data interpretation. The report consolidates expert consensus recommendations and findings from an AMP-conducted survey comparing the slice testing method with conventional static gene panels and extensive exome analyses.

The AMP Whole-Exome Sequencing Standards Working Group was formed to examine prevailing laboratory practices and formulate preliminary best practice guidelines for germline slice testing via exome approaches. These guidelines draw from a comprehensive review of current scientific literature, detailed survey results, and the firsthand knowledge of the Working Group's experts. The published manuscript, titled “Slice Testing - Considerations from Ordering to Reporting: A Joint Report of the Association for Molecular Pathology, College of American Pathologists, and National Society of Genetic Counselors,” provides an in-depth look at the practicalities, potential, and limitations of slice testing for both laboratories and clinical practitioners. These expert consensus recommendations serve as a resourceful guide, though they are not to be interpreted as a restrictive list.

“As with any emerging clinical methodology, information on slice testing is limited. This new report summarizes the current collective state of knowledge and assists clinical laboratory professionals with best practice guidance for test design and utilization,” said Susan Hsiao, MD, Ph.D., 2023 AMP Clinical Practice Committee Chair. “AMP will continue to work together with organizations like CAP and NSGC to monitor real-world evidence, share our members’ expertise, and provide the broader laboratory community with a menu of guideline resources to help improve clinical practice.”

“Slice testing is a relatively new practice that enhances flexibility in germline genetic testing for clinical laboratories and providers,” said Rong Mao, MD, Chair of the AMP Whole-Exome Sequencing Standards Working Group. “AMP will continue to reassess and modify our best practice guidance as new data and/or reference materials become available.”

Related Links:
AMP 

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Stand-Alone Disc Remover
NS96
New
EBV DNA Quantitative Fluorescence Diagnostic Kit
S3015E EBV

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The MCED test can screen for up to 42 solid tumors and five hematological tumors (Photo courtesy of 123RF)

Non-Invasive Test Detects Up To 42 Solid Tumors and Five Blood Cancers in Blood and Urine Samples

Cancer is now responsible for nearly 1 in 6 deaths worldwide. Each year, over 14 million people are diagnosed with cancer, and this number is expected to surpass 21 million by 2030. A major issue is that... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The Accelerate WAVE system delivers rapid AST directly from positive blood culture bottles (Photo courtesy of Accelerate Diagnostics)

Rapid Diagnostic System to Deliver Same-Shift Antibiotic Susceptibility Test Results

The World Health Organization estimates that sepsis impacts around 49 million people worldwide each year, resulting in roughly 11 million deaths, with about 1.32 million of these deaths directly linked... Read more

Pathology

view channel
Image: The PAXgene Urine Liquid Biopsy Set is the first standardized preanalytical workflow that stabilizes cell-free DNA in urine for subsequent analysis (Photo courtesy of PreAnalytiX)

Liquid Biopsy Solution Enables Non-Invasive Sample Collection and Direct Cell-Free DNA Stabilization from Urine

Urine cell-free DNA (cfDNA) presents significant potential for research and future clinical applications. It facilitates the measurement and analysis of cfDNA fragments, detection of genetic alterations,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.